Logo del repository
  1. Home
 
Opzioni

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

Sinnollareddy, Mahipal G.
•
Roberts, Jason A.
•
Lipman, Jeffrey
altro
BASSETTI, MATTEO
2015
  • journal article

Periodico
CRITICAL CARE
Abstract
Introduction: The objective of the study was to describe the pharmacokinetics (PK) of fluconazole, anidulafungin, and caspofungin in critically ill patients and to compare with previously published data. We also sought to determine whether contemporary fluconazole doses achieved PK/pharmacodynamic (PD; PK/PD) targets in this cohort of intensive care unit patients. Methods: The Defining Antibiotic Levels in Intensive care unit patients (DALI) study was a prospective, multicenter point-prevalence PK study. Sixty-eight intensive care units across Europe participated. Inclusion criteria were met by critically ill patients administered fluconazole (n = 15), anidulafungin (n = 9), and caspofungin (n = 7). Three blood samples (peak, mid-dose, and trough) were collected for PK/PD analysis. PK analysis was performed by using a noncompartmental approach. Results: The mean age, weight, and Acute Physiology and Chronic Health Evaluation (APACHE) II scores of the included patients were 58 years, 84 kg, and 22, respectively. Fluconazole, caspofungin, and anidulafungin showed large interindividual variability in this study. In patients receiving fluconazole, 33% did not attain the PK/PD target, ratio of free drug area under the concentration-time curve from 0 to 24 hours to minimum inhibitory concentration (fAUC0-24/MIC) ≥100. The fluconazole dose, described in milligrams per kilogram, was found to be significantly associated with achievement of fAUC0-24/MIC ≥100 (P = 0.0003). Conclusions: Considerable interindividual variability was observed for fluconazole, anidulafungin, and caspofungin. A large proportion of the patients (33%) receiving fluconazole did not attain the PK/PD target, which might be related to inadequate dosing. For anidulafungin and caspofungin, dose optimization also appears necessary to minimize variability.
DOI
10.1186/s13054-015-0758-3
WOS
WOS:000351883700001
Archivio
http://hdl.handle.net/11390/1101006
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84924359453
http://ccforum.com/content/17
Diritti
metadata only access
Soggetti
  • Aged

  • Antifungal Agent

  • Critical Illne

  • Drug Monitoring

  • Echinocandin

  • Europe

  • Female

  • Fluconazole

  • Human

  • Lipopeptide

  • Male

  • Middle Aged

  • Intensive Care Unit

  • Critical Care and Int...

Scopus© citazioni
85
Data di acquisizione
Jun 14, 2022
Vedi dettagli
Web of Science© citazioni
95
Data di acquisizione
Mar 28, 2024
google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback